Evoke Pharma (NASDAQ:EVOK) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday.
A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the company a “buy” rating in a research report on Wednesday. B. Riley reiterated a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a research report on Wednesday, November 15th. FBR & Co reiterated a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a research report on Monday, October 30th. Finally, Northland Securities reiterated a “buy” rating and set a $10.00 price objective on shares of Evoke Pharma in a research report on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.00.
Evoke Pharma (NASDAQ EVOK) remained flat at $$2.67 on Friday. The company had a trading volume of 27,243 shares, compared to its average volume of 113,730. Evoke Pharma has a 52-week low of $1.42 and a 52-week high of $4.55.
Large investors have recently made changes to their positions in the business. Sphera Funds Management LTD. raised its stake in Evoke Pharma by 14.2% during the 3rd quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after purchasing an additional 71,022 shares during the period. State Treasurer State of Michigan raised its stake in Evoke Pharma by 37.0% during the 2nd quarter. State Treasurer State of Michigan now owns 400,000 shares of the specialty pharmaceutical company’s stock valued at $1,024,000 after purchasing an additional 108,034 shares during the period. Finally, Vanguard Group Inc. raised its stake in Evoke Pharma by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 68,544 shares during the period. 13.64% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/03/evoke-pharma-evok-downgraded-by-valuengine-to-strong-sell.html.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.